Biologic Switching Strategies in Inflammatory Bowel Disease After Treatment Failure

Primary Non‑Response Management

• In patients with primary non‑response to an anti‑TNF agent, the recommendation is to switch to a biologic with a different mechanism of action rather than another anti‑TNF, based on expert consensus (86 % agreement) from the 2024 Italian IG‑IBD and SIR consensus. [1][2][3][4][5][6]7
• The preferred agents after anti‑TNF primary failure are ustekinumab or JAK inhibitors, each receiving 86 % agreement among the consensus panel. [1][2][3][4][5][6]7
• Rationale: when the underlying mechanism of action fails to produce a response, repeating the same mechanism is unlikely to be effective. (clinical expert opinion) 8

Secondary Non‑Response and Intolerance Management

• For secondary loss of response or intolerance to an anti‑TNF, three evidence‑based options achieved 100 % agreement in the same Italian IG‑IBD and SIR consensus:

Dose Escalation Options (when feasible)

• Switching to another anti‑TNF remains a viable option after secondary failure because the patient has previously responded, indicating that the mechanism works and that drug‑specific factors (pharmacokinetics, immunogenicity) are responsible for the loss of efficacy. (expert consensus) [1][2][3][4][5][6]7
• This approach is especially appropriate when the original anti‑TNF was withdrawn due to intolerance rather than loss of efficacy. (expert consensus) [1][2][3][4][5][6]7

Disease‑Specific Preferred Biologics

Ulcerative Colitis

• In biologic‑naïve ulcerative colitis, infliximab is superior to vedolizumab, adalimumab, ustekinumab, and ozanimod, based on a 2024 network meta‑analysis. (high‑grade evidence) 10
• In TNF‑exposed ulcerative colitis, upadacitinib outperforms tofacitinib, ustekinumab, vedolizumab, adalimumab, and ozanimod. (high‑grade evidence) 10

Crohn’s Disease

• For biologic‑naïve Crohn’s disease, infliximab and risankizumab are favored over ustekinumab, adalimumab, vedolizumab, and certolizumab, with no clear superiority between infliximab and risankizumab. (high‑grade evidence) 10
• In TNF‑exposed Crohn’s disease, risankizumab and upadacitinib are preferred over ustekinumab, adalimumab, and vedolizumab, again without demonstrated superiority between the two preferred agents. (high‑grade evidence) 10

Special Considerations

Extra‑intestinal Manifestations

• In patients with significant extra‑intestinal manifestations (e.g., uveitis, ankylosing spondylitis, pyoderma gangrenosum), anti‑TNF therapies remain the preferred option even after prior anti‑TNF exposure. (clinical expert opinion) 8
• Vedolizumab, because of its gut‑selective mechanism, is less effective for extra‑intestinal disease and may even exacerbate arthralgias in some cases. (expert opinion) [3][6]

Safety and Comorbidities

• For patients with multiple comorbidities or heightened infection risk, vedolizumab is often chosen due to its gut‑selective action and a lower risk of serious infections (hazard ratio 0.54; 95 % CI 0.35‑0.83 in ulcerative colitis). (moderate‑quality evidence) 11
• Ustekinumab also shows a reduced risk of serious infections compared with anti‑TNF agents (odds ratio 0.49; 95 % CI 0.25‑0.93) and with vedolizumab (odds ratio 0.40; 95 % CI 0.17‑0.93). (moderate‑quality evidence) 11

Need for Rapid Clinical Response

• When a rapid onset of action is critical, anti‑TNF agents and ustekinumab are favored over vedolizumab, which has a slower therapeutic onset. (clinical expert opinion) 8

Evidence Gaps and Consensus

• The principal limitation in current guidance is the absence of head‑to‑head randomized controlled trials directly comparing within‑class versus between‑class switching after biologic failure. (knowledge gap) [1][2][3][4][5][6]7
• The majority of available data derive from real‑world studies, retrospective analyses, and extrapolation from pivotal trials that included anti‑TNF‑exposed patients. (moderate‑quality evidence) [1][2][3][4][5][6]7
• The 2024 Italian IG‑IBD and SIR consensus achieved 77‑100 % agreement on the presented switching recommendations, representing the most up‑to‑date expert guidance. (expert consensus) [1][2][3][4][5][6]7

Upadacitinib Efficacy, Dosing, and Safety in Ulcerative Colitis

Clinical Efficacy

• Upadacitinib provides a markedly higher induction of clinical remission compared with placebo, with a relative risk of 7.15 (95 % CI 4.26‑11.99), translating to roughly 615 additional remissions per 1,000 treated patients. This estimate derives from a high‑grade network meta‑analysis. 12

Regulatory Approval & Recommended Dosing

• The U.S. Food and Drug Administration (FDA) has approved upadacitinib for moderate‑to‑severe ulcerative colitis in adults who have had an inadequate response to, or intolerance of, at least one tumor‑necrosis‑factor (TNF) antagonist. The label explicitly permits use after prior TNF‑blocker failure. 12

• Induction regimen: 45 mg orally once daily for 8 weeks.

• Maintenance regimen: Typically 15 mg or 30 mg orally once daily; however, a subset of patients may require continuation of the 45 mg daily dose to sustain response. 12

Maintenance Dose Selection

• In patients who de‑escalated from a higher to a lower JAK‑inhibitor dose (e.g., from 10 mg twice daily to 5 mg twice daily of tofacitinib), ≈ 29 % required dose re‑escalation, and only 63 % of those regained clinical response after re‑escalation. This highlights the risk of loss of efficacy with dose reduction. 12

• For individuals with a history of non‑compliance and disease flare, maintaining the 45 mg daily dose of upadacitinib is advisable rather than de‑escalating, given the demonstrated difficulty in recapturing response after dose reduction. 12

Safety Monitoring

• Dose‑dependent adverse‑event monitoring should include:

  • Herpes zoster – consider vaccination prior to initiation when not contraindicated.
  • Venous thromboembolism risk.
  • Lipid profile changes.

Adherence Advantages

• Upadacitinib’s once‑daily oral administration may improve medication adherence compared with twice‑daily regimens of other JAK inhibitors.

• Clinical remission can be achieved rapidly, with ≈ 36 % of patients attaining remission by week 2, offering early symptom relief that can reinforce continued adherence. 12

Upadacitinib: Mechanistic Rationale and Baseline Monitoring Recommendations

Mechanistic Rationale

• Upadacitinib’s greater selectivity for JAK1 and higher potency compared with other JAK inhibitors may account for its effectiveness in patients previously exposed to tofacitinib, supporting its use as a viable next‑line therapy in inflammatory bowel disease. 13

Baseline Laboratory Monitoring

• Prior to initiating upadacitinib, obtain baseline complete blood count (including neutrophils, lymphocytes, and hemoglobin), liver function tests, and a lipid panel to identify pre‑existing abnormalities and guide safety monitoring during therapy. 13